Clinical Trial Update: Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer [Phase 2, Phase 3]

View source ↗

Summary

Navtemadlin is being studied as maintenance therapy for TP53 wild-type advanced or recurrent endometrial cancer in a Phase 2/Phase 3 trial; the study is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Navtemadlin (navtemadlin)

Snippet

Sponsor: Kartos Therapeutics, Inc. | Conditions: Endometrial Cancer | Phase 2, Phase 3 | Status: RECRUITING